Article
T‐type calcium channels drive the proliferation of androgen‐receptor negative prostate cancer cells
23 Jul 2019
Abstract excerpt
BACKGROUND: Androgen deprivation therapy (ADT) is the treatment of choice for metastatic prostate cancer (PCa). After an initial response to ADT, PCa cells can generate castration resistant (CRPC) or neuroendocrine (NEPC) malignancies, which are incurable. T-type calcium channels (TTCCs) are emerging as promising therapeutic targets for several cancers, but their role in PCa progression has never been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
